metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1)
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	-1019 [-1739; -299] /10000 181/247 vs. 207/248	-206 [-751; 338] /10000 218/247 vs. 224/248	-
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	-1441 [-2258; -624] /10000 138/196 vs. 162/191	-681 [-1417; 55] /10000 157/196 vs. 166/191	-